PierFranco Conte

机构：University of Padua, Istituto Oncologico Veneto, IRCCS San Camillo Hospital · ORCID：0000-0002-5210-5344

发表论文 1235 篇 · 总被引 44072 次 · h-index 94

代表论文

• Cognitive impairment following breast cancer treatments: an umbrella review (2024 · The Oncologist · 被引 68)
• Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial (2025 · Nature Medicine · 被引 37)
• A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. (2024 · Journal of Clinical Oncology · 被引 32)
• Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial (2023 · Journal of Clinical Oncology · 被引 25)
• HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis (2025 · The Lancet Oncology · 被引 24)
• LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy (2024 · Annals of Oncology · 被引 22)